News | June 30, 2025
Biocon Biologics expands insulin access in Malaysia
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
There are 38.4 million people with diabetes in the United States
Subscribe To Our Newsletter & Stay Updated
